{"name":"Spark Therapeutics, Inc.","slug":"spark-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AAV2-hRPE65v2,voretigene neparvovec-rzyl","genericName":"AAV2-hRPE65v2,voretigene neparvovec-rzyl","slug":"aav2-hrpe65v2-voretigene-neparvovec-rzyl","indication":"Inherited retinal dystrophy caused by biallelic RPE65 mutations (Leber congenital amaurosis type 2)","status":"phase_3"},{"name":"voretigene neparvovec-rzyl","genericName":"voretigene neparvovec-rzyl","slug":"voretigene-neparvovec-rzyl","indication":"Inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations (Leber congenital amaurosis type 2)","status":"marketed"},{"name":"AAV2-hRPE65v2","genericName":"AAV2-hRPE65v2","slug":"aav2-hrpe65v2","indication":"Leber congenital amaurosis type 10, inherited retinal dystrophy","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AAV2-hCHM","genericName":"AAV2-hCHM","slug":"aav2-hchm","indication":"Leber congenital amaurosis","status":"phase_1"}]}],"pipeline":[{"name":"AAV2-hRPE65v2,voretigene neparvovec-rzyl","genericName":"AAV2-hRPE65v2,voretigene neparvovec-rzyl","slug":"aav2-hrpe65v2-voretigene-neparvovec-rzyl","phase":"phase_3","mechanism":"AAV2-hRPE65v2 is a gene therapy that delivers a functional copy of the human RPE65 gene into retinal pigment epithelium cells to restore vision in patients with inherited retinal dystrophy caused by RPE65 mutations.","indications":["Inherited retinal dystrophy caused by biallelic RPE65 mutations (Leber congenital amaurosis type 2)"],"catalyst":""},{"name":"voretigene neparvovec-rzyl","genericName":"voretigene neparvovec-rzyl","slug":"voretigene-neparvovec-rzyl","phase":"marketed","mechanism":"Voretigene neparvovec-rzyl is a gene therapy that delivers a functional copy of the RPE65 gene into retinal cells to restore vision in patients with inherited retinal dystrophy caused by RPE65 mutations.","indications":["Inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations (Leber congenital amaurosis type 2)"],"catalyst":""},{"name":"AAV2-hCHM","genericName":"AAV2-hCHM","slug":"aav2-hchm","phase":"phase_1","mechanism":"Gene therapy for Leber congenital amaurosis","indications":["Leber congenital amaurosis"],"catalyst":""},{"name":"AAV2-hRPE65v2","genericName":"AAV2-hRPE65v2","slug":"aav2-hrpe65v2","phase":"phase_2","mechanism":"AAV2-hRPE65v2 is a gene therapy that uses a viral vector to deliver a healthy copy of the RPE65 gene to the retina, treating inherited retinal dystrophy.","indications":["Leber congenital amaurosis type 10, inherited retinal dystrophy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPM0RzTEw5N3NYb0RyQkNELXM1V0U5SGZxd0pwcGY3WFdHY2xoYnltbXgwaTRKV0dXYl9xanZ4bklZYV91elEtOVVydjRsX0Y3OGZ6V2IzRFpSTnpYbUpMWk9ydTdVSVdJMHprTGJBN21DdzdncENfVXp1TGhhMktwTVFsaE9SLVlpNVFLM1JjalNGWHdQ?oc=5","date":"2025-12-26","type":"trial","source":"Ophthalmology Times Europe","summary":"The endgame of inherited retinal disease trials - Ophthalmology Times Europe","headline":"The endgame of inherited retinal disease trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNVzJpOUxrMWYtY05uWEI3akdXVllDRkNnUlNUNl9DR2VrbjFxTTZyUF9YSmtvSDB0eFhCRVFIeDJyMk9vcDFUSzlfYkRzeXJ3VHJudjM5bVBVVXR5ejNwZzJOc01ib0VvWkN3cTJKOTdLb0VXSUdhdDZ2RXo0OWFWSDZrVDRqRXU0QklSSkVoaGRsZjdCeDF5SDlPU2JjcERVajctZkluaGducUIxMHBF?oc=5","date":"2025-10-23","type":"pipeline","source":"ROI-NJ","summary":"Allen named VP, corporate affairs for North America at Sun Pharma - ROI-NJ","headline":"Allen named VP, corporate affairs for North America at Sun Pharma - ROI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQUEhKRDRqR3gtZzdzQnJZWkhyVUU0bWdOb1F4VWJpWi1CX28yLVVqWTZTRFJSWU5ROHFBeUs5UHlNYjRySDFFaWp4bkRBUkw4dWxnOElXYld2NDZzWHVOa3hyaEl3MUNSd1R4dlVPaHFDWjJCSWdXNVBsWjEybVVWSGJNb0l5eHhwM0xYZVNNaXo5TDVwbkstWm81bVNmY0Y1TUNOdGJ4dw?oc=5","date":"2025-10-20","type":"pipeline","source":"The Business Journals","summary":"Philadelphia life sciences sector cuts nearly 1,000 jobs in 2025 as investor caution grows - The Business Journals","headline":"Philadelphia life sciences sector cuts nearly 1,000 jobs in 2025 as investor caution grows","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNQ0VXUmt5SU4xd0o5NVdMMWZXVk1LRDlTUXo5SHQ1bVJqdS1IVUFibEp6R2FwRkZWUGlFby1jclhjSy1lczQ3NFl4ckh1Vlo2QV8zQjl0U1FyMUFEbFRqb3ZpQ3B3cF9PQjlMeEUxLVJFcHJxTXFLWTd1dTlOVTQzUW9CaFVxaTBkbXhSaWRfaGdCZ3ZPWExZ?oc=5","date":"2025-10-10","type":"deal","source":"The Business Journals","summary":"Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals","headline":"Bristol Myers Squibb buys Cambridge biotech for $1.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOa216d0NkRmswRS1yTlRoYXZ1ZG0tT2stQVNvaVg0QzlFMERvU3VadlJSUHZYNWNmVkVDNm80bFdKRWNsd0g2TFE3TUpCX3dzeDNWUDRwM2xQSVk2ZFpOcHl5ODQ0ekxuZHBHeXQtcTBrd3hwU29va0N3RFhtRU9VbGYzTkZxZ2laRHZPQkFUN1FSdVIzU3V2Z0p6MHByNFhSM0t0VnJ3Zw?oc=5","date":"2025-05-07","type":"pipeline","source":"BioSpace","summary":"Hiring Outlook: Biopharma Job Market Yet To Surge, but Layoffs Decline - BioSpace","headline":"Hiring Outlook: Biopharma Job Market Yet To Surge, but Layoffs Decline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQZXNqYmdVam5Na0ljck1XQmREa0JoWW1HRk4tYmFtbTVzLThRdU8tRElTMWY0cVJDUjU4bWdQT1c0MzNhWkNNQjNZOU1jUXRDMkNua3ViTDRXX1Foc2xCbHg1MzJSUTV2aTdCVlZEOWVHUTBXRlYxTTRkNUJNdUN0Sy1zbw?oc=5","date":"2025-03-17","type":"pipeline","source":"technical.ly","summary":"Does the Spark Therapeutics writedown undermine Philly’s biotech swagger? - technical.ly","headline":"Does the Spark Therapeutics writedown undermine Philly’s biotech swagger?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1FSeXlFamZseUNEWVItQ3psajBCb3d0a0NyVFRXLXR1N0ctajlzYnhFTDVyV2N6RHR6Mkk3dXRfcnFpTTJMN1B4ejZOaVNXcHlrYXA0eFhSRDRreGJOeU96Vko0bERRMElpWm84bE9jZzI2V1JWZDZfS0pXNHJielBfVm11SndyUUx3Rk5FTkh5SnhDcC1KU1l5THlPek9NRGh4bG1JVmo?oc=5","date":"2025-03-10","type":"pipeline","source":"Fierce Pharma","summary":"UPDATE: Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment - Fierce Pharma","headline":"UPDATE: Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPbWtYMllkMFBaTnl5clFjOE1qUU5NTnc1T1M2d3RxaDR6ZFU2NUpBTWRMNVZRQnh0TTVWT1M2Nk5CbndRdkkwQVJYSDhLeC1rWHVqVlJZdzRBT3ZyVjA2enBmS3lEVFdjRjR6WnhSZmFTTzlHX1pkUnVoR3g4WGt3V1VfMFF4ZWFnaXJHNQ?oc=5","date":"2025-03-04","type":"pipeline","source":"Inquirer.com","summary":"Spark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downs - Inquirer.com","headline":"Spark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNndONkM4bFJGbGU3THhERjBIalNtVFhVaXNHY0tKYlg3MUJKdldWLVdTdWdKVlEyYUd4NXRtc05iM19vTF9wMG4ySU9HT2pVcW16Rkx3TzZSNnVPU0V2bEFDRFhOSFIyU0FBU1JsVUlZOVRhRVU1RlItWHo2VzR6WVg4cTNESUh1V0Q0Y2h6TkZsWWZ1S0lad2dGNHF2djhyMURfTmhTREE0N0U?oc=5","date":"2023-10-17","type":"deal","source":"Pharmaceutical Technology","summary":"Spark Therapeutics partners with SpliceBio for gene therapy - Pharmaceutical Technology","headline":"Spark Therapeutics partners with SpliceBio for gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQc2p5OGFrYjc1SVhKc1lvanh6WHk2TVF1ZkpQN2NlaFRIM0ZhV2JKQUZmYXBib1BHMXp3UWtoQm5EWE1qVC1LRFNBSVpuRlNXeDFEaUhQYlZNYVhpTmJFd2ZRQUlJY3pzYXF6a0tJTFBDUnJaNWQ3LW12MVRYYTJqRWt5WjRtNVoybTJmOEs1STZRQW50?oc=5","date":"2022-02-23","type":"regulatory","source":"BioPharma Dive","summary":"Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down - BioPharma Dive","headline":"Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQdnZpU1VDeEF6U0tvQTBjenVWTnotY3FxbVJZdjZTVkoxNWhxc2puSHQ4Rno0SzlDOHlJNWYwM1dBdjhKVXpSTWU3aHpmaGg2blZDMEVyT3E3MzYtVk0wZk51ZV9BQkhxVXpzZ2hnc0tuODdsNmJzQUVkZU4xcnBuMkU4b2lrSzFKc2dCR09VZ0JLRlR3VDhMUXVpTjlxTkZqMjRv?oc=5","date":"2019-02-25","type":"pipeline","source":"Business Insider","summary":"Pharma giant Roche just bought biotech firm Spark, the maker of an $850,000 eye drug - Business Insider","headline":"Pharma giant Roche just bought biotech firm Spark, the maker of an $850,000 eye drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQaXhMYWNjQmprYnZ4bmtLckIwZkRVM2FSblBaSWVQS2FRblB0eXVLNThkWlJZN19XXzg5dkZVa0lzX1VER19WZHFfWTdjS1NqMEdITWtBbC03OWVrMVVXd09EWVEybkNMSUx3S2RDa0hBLWJ1V25sVTZod0ZmcVJnd2ptSE8tSUdEUFdNUXdMTlNnN1ktVzlXaEdzVExnUXhocnNRaGlCci1kRHlWVmhZ?oc=5","date":"2019-02-23","type":"deal","source":"Bloomberg.com","summary":"Roche Nears $5 Billion Deal to Buy Spark Therapeutics: WSJ - Bloomberg.com","headline":"Roche Nears $5 Billion Deal to Buy Spark Therapeutics: WSJ","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"marketed":1,"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}